Table II. Comparison of clinical data between patients with haplotype DQA1*0104/DQB1*0503/DRB1*1405 and patients with other haplotypes.
| Variables | Total (n = 72) | Patients with Haplotype DQA1*0104/DQB1*0503/DRB1*1405 (n = 37) | Patients with Other Haplotypes (n = 35) | p Value |
|---|---|---|---|---|
| Age (y) | 48.5 ± 11.2 | 48.4 ± 11.4 | 48.7 ± 11.1 | 0.88 |
| Female (%) | 49 (68.1) | 27 (73.0) | 22 (62.9) | 0.36 |
| Allergic history, n (%) | 33 (45.8) | 11 (29.7) | 12 (34.3) | 0.68 |
| Culprit drug history, n (%) | 57 (79.2) | 31 (83.8) | 26 (74.3) | 0.32 |
| Allergic symptoms, n (%)a | 59 (81.9) | 33 (89.2) | 26 (74.3) | 0.10 |
| CRP (mg/l) | 14.0 (4.0, 27.1) | 14.0 (8.4, 29.8) | 12.1 (2.6, 23.1) | 0.33 |
| ESR (mm/h) | 66.0 (36.0, 97.0) | 76.5 (47.5, 100.5) | 50.0 (27.0, 94.0) | 0.07 |
| IgG (g/l) | 16.0 (11.0, 19.0) | 16.0 (11.0, 18.5) | 15.0 (10.0, 20.0) | 0.89 |
| Peak Scr (μmol/l) | 263.5 (186.3, 438.3) | 320.0 (227.0, 506.0) | 222.0 (177.0, 323.0) | 0.01 |
| Scr at biopsy (μmol/l) | 232.5 (164.5, 351.4) | 264.0 (183.0, 424.0) | 197.0 (155.0, 273.5) | 0.03 |
| RRT rate (%) | 12 (16.7) | 9 (24.3) | 3 (8.6) | 0.07 |
| Renal glycosuria (%) | 56 (77.8) | 32 (86.5) | 24 (68.6) | 0.07 |
| NAG (U/l) | 21.5 (12.8, 52.3) | 19.0 (12.0, 57.0) | 26.0 (14.0, 51.0) | 0.39 |
| Urinary α1-MG (mg/l) | 199.0 (124.5, 279.3) | 213.5 (144.0, 307.5) | 172.0 (36.0, 238.8) | 0.06 |
| Renal pathology | ||||
| Tubular | ||||
| PTEC necrosis and falling | 0.9 ± 0.8 | 1.1 ± 0.7 | 0.9 ± 0.8 | 0.21 |
| Regeneration | 0.8 ± 0.9 | 0.6 ± 0.8 | 1.0 ± 1.0 | 0.09 |
| Tubular atrophy | 0.8 ± 0.9 | 0.6 ± 0.8 | 1.0 ± 1.0 | 0.09 |
| Interstitial | ||||
| Interstitial edema | 0.6 ± 0.5 | 0.7 ± 0.4 | 0.5 ± 0.5 | 0.09 |
| Inflammatory cell infiltration | 0.2 ± 0.5 | 0.4 ± 0.7 | 0.1 ± 0.3 | 0.03 |
| Eosinophils | 0.8 ± 0.4 | 0.8 ± 0.4 | 0.7 ± 0.5 | 0.50 |
| Tubulitis | 0.2 ± 0.5 | 0.4 ± 0.7 | 0.1 ± 0.3 | 0.03 |
| Interstitial fibrosis | 0.5 ± 0.9 | 0.5 ± 0.9 | 0.5 ± 0.9 | 0.95 |
| Prednisone (%) | 39(56.5) | 18 (51.4) | 21 (61.8) | 0.47 |
| MP impulse (%) | 9 (8.5) | 26 (74.3) | 6 (17.6) | <0.001 |
| CTX/MMF (%) | 14 (20.3) | 9 (25.7) | 5 (14.7) | 0.26 |
| Scr at 1 mo (μmol/l) | 126.0 (109.0, 161.0) | 131.0 (114.8, 161.5) | 114.5 (106.3, 153.8) | 0.08 |
| Scr declination by 1 m (%) | 40.7 ± 24.1 | 44.1 ± 20.5 | 35.9 ± 28.1 | 0.20 |
| eGFR at 12 mo (ml/min) | 61.4 ± 20.9 | 61.8 ± 22.1 | 60.8 ± 19.9 | 0.86 |
C-reactive protein (CRP), normal range, <8 mg/l; erythrocyte sedimentation rate (ESR), normal range (male), <15 mm/h; normal range (female), <20 mm/h; IgG, normal range, 7.23–16.85 g/l; Scr normal range, 44–133 mmol/l; N-acetyl-β-d-glucosaminidase (NAG), normal range, 0–21 U/l; α1-microglobulin (α1-MG), normal range, 0–12 mg/l.
Bold indicates statistical significance.
a
Allergic symptoms include fever, rash, arthralgia, or eosinophilia.
CTX, cyclophasphamide; MMF, mycophenolate mofetil; MP, methylprednisolone; PTEC, proximal tubular epithelial cell; RRT, renal replacement therapy.